-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

Richard Douglas, PhD
Director
Dr. Douglas joined the Novavax board of directors in 2010. He has more than 25 years of biotechnology experience having served in corporate development roles at Genzyme Corporation since 1989. Most recently, Dr. Douglas was senior vice president of corporate development and a corporate officer at Genzyme Corporation. As a leader of Genzyme’s corporate development team, Dr. Douglas was involved in numerous acquisitions, licenses, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989, Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Dr. Douglas was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology. He received a BS in chemistry from the University of Michigan and a PhD from the University of California, Berkeley in biochemistry. He currently serves on the University of Michigan Technology Transfer National Advisory Board.